Literature DB >> 24769484

Early and late changes in quality of life following transcatheter aortic valve implantation using the transfemoral and transapical approaches.

Veronica Bona1, Muhammed Z Khawaja, Vinayak Bapat, Christopher Young, Jane Hancock, Simon Redwood, Melissa Fusari, Martyn Thomas.   

Abstract

AIMS: To evaluate the effects of access route upon clinical results and quality of life (QoL) in patients undergoing either transfemoral (TF-TAVI) or transapical balloon-expandable transcatheter aortic valve implantation (TA-TAVI) in the real world. METHODS AND
RESULTS: A prospective analysis was performed upon 264 consecutive patients receiving TF-TAVI or TA-TAVI. QoL was assessed using the EQ-5D questionnaire. At baseline, TA-TAVI patients reported significantly more problems in mobility, self-care, usual activities and lower overall health status domains (p<0.01 for all). At 30 days, the TF-TAVI group reported fewer problems with usual activity (p=0.01) and pain/discomfort (p<0.01), and higher EQ-5D index and visual analogue scale (VAS) (p=0.01 and p<0.01, respectively) than the TA-TAVI group. Nevertheless, the absolute improvements (ΔEQ-5D index and ΔEQ-5D VAS) were larger in the TA-TAVI group, with most dramatically marked QoL absolute improvements (p<0.01 and p=0.02, respectively). By one year, notwithstanding higher all-cause mortality in the sicker TA-TAVI group, there were no differences between groups in any EQ-5D domain. Indeed, surviving TA-TAVI group's greater absolute improvements remained (p<0.01).
CONCLUSIONS: QoL is greater at the earlier time point of 30 days in the TF-TAVI cohort but equatable by one year. However, the magnitude of improvement in QoL is greater in the TA-TAVI patients at both 30 days and one year.

Entities:  

Mesh:

Year:  2015        PMID: 24769484     DOI: 10.4244/EIJV11I2A41

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  3 in total

1.  Temporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement: A Placement of AoRTic TraNscathetER Valve (PARTNER) Trial Substudy.

Authors:  Hemal Gada; Ajay J Kirtane; Kaijun Wang; Yang Lei; Elizabeth Magnuson; Matthew R Reynolds; Mathew R Williams; Susheel Kodali; Torsten P Vahl; Suzanne V Arnold; Martin B Leon; Vinod Thourani; Wilson Y Szeto; David J Cohen
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-09

2.  Health-related quality of life following transcatheter aortic valve implantation using transaortic, transfemoral approaches and surgical aortic valve replacement-a single-center study.

Authors:  Aleksandra Stańska; Dariusz Jagielak; Maciej Kowalik; Maciej Brzeziński; Rafał Pawlaczyk; Jadwiga Fijałkowska; Wojciech Karolak; Jan Rogowski; Peter Bramlage
Journal:  J Geriatr Cardiol       Date:  2018-11       Impact factor: 3.327

3.  Trial protocol for the validation of the 'Toronto Aortic Stenosis Quality of Life (TASQ) Questionnaire' in patients undergoing surgical aortic valve replacement (SAVR) or transfemoral (TF) transcatheter aortic valve implantation (TAVI): the TASQ registry.

Authors:  Derk Frank; Simon Kennon; Nikolaos Bonaros; Mauro Romano; Thierry Lefèvre; Carlo Di Mario; Pierluigi Stefàno; Flavio Luciano Ribichini; Dominique Himbert; Marina Urena-Alcazar; Jorge Salgado-Fernandez; Jose Joaquin Cuenca Castillo; Bruno Garcia; Jana Kurucova; Martin Thoenes; Claudia Lüske; Peter Bramlage; Rima Styra
Journal:  Open Heart       Date:  2019-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.